These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34548818)

  • 1. Low Dose of Lenvatinib Treatment for Patients of Radioiodine-Refractory Differentiated Thyroid Carcinoma - A Real-World Experience.
    Jiang HJ; Chang YH; Chen YH; Wu CW; Wang PW; Hsiao PJ
    Cancer Manag Res; 2021; 13():7139-7148. PubMed ID: 34548818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea.
    Song E; Kim M; Kim EY; Kim BH; Shin DY; Kang HC; Ahn BC; Kim WB; Shong YK; Jeon MJ; Lim DJ
    Thyroid; 2020 May; 30(5):732-738. PubMed ID: 31910091
    [No Abstract]   [Full Text] [Related]  

  • 3. Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria.
    Rendl G; Sipos B; Becherer A; Sorko S; Trummer C; Raderer M; Hitzl W; Ardelt M; Gallowitsch HJ; Pirich C
    Int J Endocrinol; 2020; 2020():8834148. PubMed ID: 33312196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer.
    Tahara M; Brose MS; Wirth LJ; Suzuki T; Miyagishi H; Fujino K; Dutcus CE; Gianoukakis A
    Eur J Cancer; 2019 Jan; 106():61-68. PubMed ID: 30471649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
    Oh HS; Shin DY; Kim M; Park SY; Kim TH; Kim BH; Kim EY; Kim WB; Chung JH; Shong YK; Lim DJ; Kim WG
    Thyroid; 2019 Dec; 29(12):1804-1810. PubMed ID: 31592739
    [No Abstract]   [Full Text] [Related]  

  • 6. Real-world analysis of the use of lenvatinib in differentiated thyroid cancers.
    Peelay Z; Parekh D; Patil VM; Noronha V; Menon N; Prabhash K
    Ecancermedicalscience; 2023; 17():1500. PubMed ID: 36816785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer.
    Koehler VF; Berg E; Adam P; Weber GL; Pfestroff A; Luster M; Kutsch JM; Lapa C; Sandner B; Rayes N; Fuss CT; Kreissl MC; Hoster E; Allelein S; Schott M; Todica A; Fassnacht M; Kroiss M; Spitzweg C
    Thyroid; 2021 Oct; 31(10):1531-1541. PubMed ID: 34405734
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial.
    Brose MS; Worden FP; Newbold KL; Guo M; Hurria A
    J Clin Oncol; 2017 Aug; 35(23):2692-2699. PubMed ID: 28613956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study.
    Matsuyama C; Enokida T; Ueda Y; Suzuki S; Fujisawa T; Ito K; Okano S; Tahara M
    Front Oncol; 2023; 13():1139659. PubMed ID: 37886165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of 8 weeks' relative dose intensity of lenvatinib in treatment of radioiodine-refractory differentiated thyroid cancer patients.
    Fukuda N; Toda K; Wang X; Ohmoto A; Hayashi N; Urasaki T; Sato Y; Nakano K; Ono M; Tomomatsu J; Mitani H; Takahashi S
    Endocr J; 2021 Jun; 68(6):639-647. PubMed ID: 33504716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in Real-Life Practice.
    Berdelou A; Borget I; Godbert Y; Nguyen T; Garcia ME; Chougnet CN; Ferru A; Buffet C; Chabre O; Huillard O; Leboulleux S; Schlumberger M
    Thyroid; 2018 Jan; 28(1):72-78. PubMed ID: 29048237
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and Limitations of Lenvatinib Therapy for Radioiodine-Refractory Differentiated Thyroid Cancer: Real-World Experiences.
    Masaki C; Sugino K; Saito N; Akaishi J; Hames KY; Tomoda C; Suzuki A; Matsuzu K; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Ito K
    Thyroid; 2020 Feb; 30(2):214-221. PubMed ID: 31854270
    [No Abstract]   [Full Text] [Related]  

  • 13. OPTIMIZING LENVATINIB THERAPY IN PATIENTS WITH METASTATIC RADIOACTIVE IODINE-RESISTANT DIFFERENTIATED THYROID CANCERS.
    Jasim S; Iniguez-Ariza NM; Hilger CR; Chintakuntlawar AV; Ryder MM; Morris JC; Bible KC
    Endocr Pract; 2017 Oct; 23(10):1254-1261. PubMed ID: 28816536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy.
    Locati LD; Piovesan A; Durante C; Bregni M; Castagna MG; Zovato S; Giusti M; Ibrahim T; Puxeddu E; Fedele G; Pellegriti G; Rinaldi G; Giuffrida D; Verderame F; Bertolini F; Bergamini C; Nervo A; Grani G; Rizzati S; Morelli S; Puliafito I; Elisei R
    Eur J Cancer; 2019 Sep; 118():35-40. PubMed ID: 31299580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
    Wirth LJ; Tahara M; Robinson B; Francis S; Brose MS; Habra MA; Newbold K; Kiyota N; Dutcus CE; Mathias E; Guo M; Sherman SI; Schlumberger M
    Cancer; 2018 Jun; 124(11):2365-2372. PubMed ID: 29656442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological Features Predict Outcomes in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Real-World Study.
    Cheng L; Fu H; Jin Y; Sa R; Chen L
    Oncologist; 2020 Apr; 25(4):e668-e678. PubMed ID: 31957916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to Lenvatinib in Children with Papillary Thyroid Carcinoma.
    Mahajan P; Dawrant J; Kheradpour A; Quintanilla NM; Lopez ME; Orth RC; Athanassaki I; Venkatramani R
    Thyroid; 2018 Nov; 28(11):1450-1454. PubMed ID: 30226445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenvatinib complementary with radioiodine therapy for patients with advanced differentiated thyroid carcinoma: case reports and literature review.
    Sheu NW; Jiang HJ; Wu CW; Chiang FY; Chiou HC; Hsiao PJ
    World J Surg Oncol; 2019 May; 17(1):84. PubMed ID: 31103041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of lenvatinib in a series of advanced well-differentiated thyroid carcinomas from a single tertiary cancer center and literature review.
    Damásio IL; Figueiredo A; Maciel J; Horta M; Silva TN; Simões-Pereira J; Donato S; Leite V
    Minerva Endocrinol (Torino); 2024 Mar; ():. PubMed ID: 38512702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
    Schlumberger M; Tahara M; Wirth LJ; Robinson B; Brose MS; Elisei R; Habra MA; Newbold K; Shah MH; Hoff AO; Gianoukakis AG; Kiyota N; Taylor MH; Kim SB; Krzyzanowska MK; Dutcus CE; de las Heras B; Zhu J; Sherman SI
    N Engl J Med; 2015 Feb; 372(7):621-30. PubMed ID: 25671254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.